$6.99
-0.56-7.42%
Last update: Nov 9, 5:25 PM
AgomAb Therapeutics NV (AGMB) Stock Price, Quote, News & History
AGMBNASDAQ
Agomab Therapeutics reports positive 48-week Phase 2a trial data for ontunisertib in patients with fibrostenotic Crohn's disease.
You can purchase shares of AgomAb Therapeutics (NASDAQ:AGMB) through any online brokerage.
Other companies in AgomAb Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
AgomAb Therapeutics has a consensus price target of $37.50.
The stock price for AgomAb Therapeutics (NASDAQ: AGMB) is $7.45 last updated November 9, 2026 at 5:25 PM EST.
There are no upcoming dividends for AgomAb Therapeutics.
AgomAb Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for AgomAb Therapeutics.
AgomAb Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need....
